Patients who need anti-VEGF injections shoulder a significant burden that  has retinal specialists increasingly concerned, especially when some patients lose hope and their commitment to treatment wanes. So says David Boyer, MD, a senior partner at the Retina-Vitreous Associates Medical Group, based in Los Angeles and surrounding areas. “This is like getting chemo,” he adds. “These patients have to make visits every six or seven weeks. After three years or so, they get tired. With FDA approval in October 2019 of brolucizumab (Beovu, Novartis)—ostensibly the most durable anti-VEGF drug of five that have been used during the past 15 years and the first to be approved since 2011—ophthalmologists and patients look to a future when the burden of continual anti-VEGF injections lightens. Read More